CIK 0001576885 · <br>Emerging growth company
Acumen Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ABOS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364108129
- Phone
- 617-344-4190
- Business address
- 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-19 | OConnell Daniel Joseph President and CEO | Sale 10b5-1 | −15,200 | $3.47 | $53K | 502,485 |
| 2024-01-19 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale 10b5-1 | −8,933 | $3.48 | $31K | 108,867 |
| 2024-01-18 | Zuga Matt CFO & Chief Business Officer | Sale 10b5-1 | −4,242 | $3.71 | $16K | 211,445 |
| 2024-01-18 | Siemers Eric Chief Medical Officer | Sale 10b5-1 | −3,124 | $3.71 | $12K | 117,576 |
| 2024-01-18 | Barton Russell Chief Operating Officer | Sale 10b5-1 | −2,833 | $3.73 | $11K | 96,867 |
| 2024-01-02 | Barton Russell Chief Operating Officer | Grant or award | +73,000 | 99,700 | ||
| 2024-01-02 | Barton Russell Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2024-01-02 | Meisner Derek M Chief Legal Officer & Corp Sec | Grant or award | +91,000 | 117,800 | ||
| 2024-01-02 | Meisner Derek M Chief Legal Officer & Corp Sec | Grant or award · Employee Stock Option (right to buy) | +137,000 | 137,000 | ||
| 2024-01-02 | Siemers Eric Chief Medical Officer | Grant or award | +94,000 | 120,700 | ||
| 2024-01-02 | Siemers Eric Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +141,000 | 141,000 | ||
| 2024-01-02 | Zuga Matt CFO & Chief Business Officer | Grant or award | +106,000 | 215,687 | ||
| 2024-01-02 | Zuga Matt CFO & Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +159,000 | 159,000 | ||
| 2024-01-02 | OConnell Daniel Joseph President and CEO | Grant or award | +401,000 | 517,685 | ||
| 2024-01-02 | OConnell Daniel Joseph President and CEO | Grant or award · Employee Stock Option (right to buy) | +602,000 | 602,000 | ||
| 2023-08-17 | Ives Jeffrey L. Director | Option exercise 10b5-1 | +39,149 | $0.72 | $28K | 39,149 |
| 2023-08-17 | Ives Jeffrey L. Director | Sale 10b5-1 | −39,149 | $6.48 | $254K | 0 |
| 2023-08-17 | Ives Jeffrey L. Director | Option exercise 10b5-1 | +2,800 | $1.19 | $3K | 2,800 |
| 2023-08-17 | Ives Jeffrey L. Director | Sale 10b5-1 | −2,800 | $6.66 | $19K | 0 |
| 2023-08-17 | Ives Jeffrey L. Director | Option exercise · Stock Option (right to buy) 10b5-1 | −39,149 | 0 |
Page 8 of 13 · 246 trades